Janssen Pharmaceutica Nv

Astex Therapeutics Limited

Timothy Pietro Suren Perera

Eddy Jean Edgard Freyne

Werner Constant Johan Embrechts

Lieven Meerpoel

Kristof Van Emelen

Jean Fernand Armand Lacrampe

Marc Willems

Ronaldus Arnodus Hendrika Joseph Gilissen

Patrick René Angibaud

Christopher William Murray

Valerio Berdini

Gordon Saxty

Isabelle Noëlle Constance Pilatte

Laurence Anne Mevellec

Gilbert Besong

Peter Ten Holte

Steven John Woodhead

Peter Jacobus Johannes Antonius Buijnsters

Berthold Wroblowski

Pascal Ghislain André Bonnet

Alexandra Papanikos

Rhalid Akkari

Eleonora Jovcheva

Christopher Norbert Johnson

Virginie Sophie Poncelet

Olivier Alexis Georges Querolle

David Charles Rees

Gaston Stanislas Marcella Diels

Christopher Charles Frederick Hamlett

Elisabeth Thérèse Jeanne Pasquier

Pierre Henri Storck

Peter Jacobus Johannes Buijnsters

Michael Reader

Frederik Jan Rita Rombouts

Johan Erwin Edmond Weerts

Delphine Yvonne Raymonde Lardeau

Yannick Aimé Eddy Ligny

Tom Cornelis Hortense Govaerts

Philip James Pye

Patrick Blasius Furer

Carsten Schultz-Fademrecht

Tom Lavrijssen

Eddy J Freyne

Ioannis Nicolaos Houpis

Ioannnis Nicolaos Houpis

Peter Jacobus Johnnes Antonius Buijnsters

Kristof Van Emelem

Oliver Alexis Georges Querolle

Peter Jacobus Johannes Antonius

Gilbert Ebai Besong

Matthias Luc Aimé Versele

Robby Ruijtenbeek

Willem Jan-Paul Edmond Talloen

René Houtman

Carsten Schulz-Fademrecht

Frederk Jan Rita Rombouts

The invention relates to a combination of a first compound selected from N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof; and a second compound which is a cMet inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for use in the treatment of cancer. The FGFR inhibitor (N-(3,5-dimethoxyphenyl)-N-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof) and the cMet inhibitor can be administered simultaneously, separately or sequentially. The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.

Combination of an FGFR inhibitor and a CMET inhibitor

The invention relates to a combination of a FGFR inhibitor and an IGF1R inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for the treatment of cancer. The FGFR inhibitor and the IGFR inhibitor can be administered simultaneously, separately or sequentially. The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.

Combinations of an FGFR inhibitor and an IGF1R inhibitor

The invention relates to a combination of a first compound selected from N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof; and a second compound which is a cMet inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for use in the treatment of cancer. The FGFR inhibitor (N-(3,5-dimethoxyphenyl)-N&#x2032;-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof) and the cMet inhibitor can be administered simultaneously, separately or sequentially. The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.

Combinations

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Pyrazolyl quinoxaline kinase inhibitors

The invention is directed to a triazolopyridazine compound of formula (I): N-oxides, pharmaceutically acceptable salts and solvates thereof, wherein D represents deuterium, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Deuterated triazolopyridazine as a kinase modulator

The invention is directed to a triazolopyridazine compound of formula (I), N-oxides, pharmaceutically acceptable salts and solvates thereof, wherein D represents deuterium, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders. 

The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

3-cyano-quinoline derivatives with antiproliferative activity

The present invention concerns the compounds of formula wherein

Quinazoline derivatives

The present invention concerns the compounds of formula 

Pyrido and pyrimidopyrimidine derivatives as anti-profilerative agents

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. 

Growing community of inventors

Geel, Belgium

Timothy Pietro Suren Perera